Context Therapeutics: Delivering treatments in the female oncology space

United in its passion for helping women with cancer and specializing in the development of potentially first-in-class medicines, Context Therapeutics has embarked on a mission to develop treatments for patients with hormone-driven cancers.

In August 2022, Context announced a clinical trial collaboration and supply agreement with the Menarini Group to evaluate ONA-XR in combination with Menarini’s oral selective estrogen receptor degrader, elacestrant.

In this video, Context Therapeutics’ CEO and Co-founder, Martin Lehr, and Menarini Group CEO, Elcin Barker Ergun, discuss the collaboration.

For more information, visit Edison’s profile page for Context Therapeutics and see the latest update.

Want to receive content on Context Therapeutics? Complete the form below.